Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
Summary
Reactive oxygen species (ROS) act as critical secondary messengers in various intracellular signaling pathways that regulate cellular proliferation, differentiation, and survival under normal physiological conditions. However, dysregulation of redox signaling-driven by genetic mutations, epigenetic alterations, and posttranscriptional or posttranslational modifications-plays a central role in malignant transformation and cancer progression. Cancer cells typically exhibit elevated basal ROS
Content
# Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
*Published: 2026 Mar 18*
Reactive oxygen species (ROS) act as critical secondary messengers in various
intracellular signaling pathways that regulate cellular proliferation,
differentiation, and survival under normal physiological conditions. However,
dysregulation of redox signaling-driven by genetic mutations, epigenetic
alterations, and posttranscriptional or posttranslational modifications-plays a
central role in malignant transformation and cancer progression. Cancer cells
typically exhibit elevated basal ROS levels due to increased metabolic activity,
mitochondrial dysfunction, and oncogene activation. This moderate oxidative
stress promotes tumorigenesis by inducing DNA damage, genomic instability, and
aberrant activation of proliferative and survival pathways, while also
contributing to resistance to conventional therapies. Paradoxically, excessive
ROS accumulation can overwhelm antioxidant defenses, triggering oxidative
stress-induced programmed cell death (PCD) mechanisms, including apoptosis,
autophagy, and ferroptosis. Owing to its dual role-facilitating both tumor
progression and suppression-ROS have emerged as compelling yet complex targets
in cancer therapy. Therapeutic strategies aimed at modulating ROS homeostasis,
such as enhancing ROS production, inhibiting antioxidant systems, or targeting
downstream redox-regulated signaling nodes, hold promise for selectively
eliminating cancer cells. Furthermore, integrating redox profiling or "redox
signatures" into personalized medicine approaches may optimize therapeutic
efficacy while minimizing off-target toxicity. In this review, we critically
examine the Janus-faced role of ROS in carcinogenesis, dissect the molecular
pathways regulated by ROS in tumor biology, and explore current advancements,
limitations, and future directions in redox-based anticancer therapeutic
approaches.
DOI: 10.1038/s41392-026-02583-x